Skip to main content
Premium Trial:

Request an Annual Quote

Quest Deal for Celera Clears US Antitrust Review

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that its proposed acquisition of Celera has cleared US antitrust review.

The firm said that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with the deal, satisfying one of the conditions necessary to close the transaction.

Quest made the offer last month to acquire Celera for $8 per share. The total value of the deal is $671 million, or $344 million net of cash and short-term investments.

The firms said today that the offer is still scheduled to expire at 5:00 p.m., New York City time on April 25, unless it is extended. However, the deal has been challenged by certain shareholders, who believe the purchase price does not adequately value Celera's assets.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more